Table 4. Financial implications of de-escalation. Patients with molecular recurrence: UPN At trial entry: Cohort TKI cost without Months to Total months at Actual TKI TKI cost saved recurrence half dose cost (£) (£) TKI Dose 8 Imatinib daily MMR 10.2 10.4 10104 22 Imatinib 300mg daily MMR 17775 12.0 13.8 6699 23 Imatinib 400mg daily MMR 23700 8.0 8.3 15643 8058 44 Imatinib daily MMR 23700 4.1 4.1 19736 3965 51 Imatinib 400mg daily MMR 4.8 5.3 18521 5180 76 Imatinib 300mg daily MMR 17775 4.3 4.3 15697 2078 79 Imatinib 400mg daily MMR 23700 2.5 3.1 20663 3038 107 Imatinib daily MMR 23700 3.2 3.2 20599 3102 138 Imatinib 400mg daily MMR 23700 5.9 5.9 17913 5788 28 Imatinib 400mg daily MR4 23700 8.6 8.9 15003 8697 89 Imatinib 400mg daily MR4 23700 8.0 8.1 7930 99 Imatinib 400mg daily MR4 23700 12.0 12.6 11390 12311 Patients completing 12 months of de-escalation without molecular recurrence: No. of patients At trial entry: TKI cost without de-escalation (£) Total TKI cost saved (£) TKI Dose 120 Imatinib 400mg daily 2844085 1422064 1 Imatinib 350mg daily 8888 11 Imatinib 300mg daily 195528 65176 1 Imatinib 250mg daily 2962 3 Imatinib daily 35551 0 10 Nilotinib 400mg twice daily 317356 158678 4 Nilotinib twice daily 126942 63471 1 Nilotinib twice daily 7934 1 Nilotinib 200mg twice daily 15868 0 8 Dasatinib 100mg daily 243983 121992 1 Dasatinib 80mg daily 15249 1 Dasatinib 50mg daily 15249 0
Table 4. Financial implications of de-escalation. Patients with molecular recurrence: UPN At trial entry: Cohort TKI cost without Months to recurrence Total months at half dose Actual TKI cost (£) TKI cost saved (£) TKI Dose 8 Imatinib daily MMR 10.2 10.4 10104 22 Imatinib 300mg daily MMR 17775 12.0 13.8 6699 23 Imatinib 400mg daily MMR 23700 8.0 8.3 15643 8058 44 Imatinib daily MMR 23700 4.1 4.1 19736 3965 51 Imatinib 400mg daily MMR 4.8 5.3 18521 5180 76 Imatinib 300mg daily MMR 17775 4.3 4.3 15697 2078 79 Imatinib 400mg daily MMR 23700 2.5 3.1 20663 3038 107 Imatinib daily MMR 23700 3.2 3.2 20599 3102 138 Imatinib 400mg daily MMR 23700 5.9 5.9 17913 5788 28 Imatinib 400mg daily MR4 23700 8.6 8.9 15003 8697 89 Imatinib 400mg daily MR4 23700 8.0 8.1 7930 99 Imatinib 400mg daily MR4 23700 12.0 12.6 11390 12311 Patients completing 12 months of de-escalation without molecular recurrence: No. of patients At trial entry: TKI cost without de-escalation (£) Total TKI cost saved (£) TKI Dose 120 Imatinib 400mg daily 2844085 1422064 1 Imatinib 350mg daily 8888 11 Imatinib 300mg daily 195528 65176 1 Imatinib 250mg daily 2962 3 Imatinib daily 35551 0 10 Nilotinib 400mg twice daily 317356 158678 4 Nilotinib twice daily 126942 63471 1 Nilotinib twice daily 7934 1 Nilotinib 200mg twice daily 15868 0 8 Dasatinib 100mg daily 243983 121992 1 Dasatinib 80mg daily 15249 1 Dasatinib 50mg daily 15249 0
paper174%202nd%20revision%20Lancet%20Haematology%20FINAL%20with%20tracked%20changes.docx